Debio 2512
/ Debiopharm, SunRock Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 30, 2025
Debiopharm…announced having signed a license agreement for SunRock Biopharma’s SRB21, an HER3/HER2 antibody
(Businesswire)
- "Debiopharm has exercised its option to license SunRock Biopharma's bispecific antibody, which targets both HER2 and HER3 human epidermal growth factor receptors. This agreement, initially announced in 2023, will combine this antibody with Debiopharm's proprietary MultiLINK Linker Technology to develop a new antibody-drug conjugate (ADC) under the name Debio 2512."
Licensing / partnership • New molecule • Oncology
1 to 1
Of
1
Go to page
1